| Literature DB >> 22529809 |
Christoph Rockel1, Thomas Hartung.
Abstract
Fifty years after the elucidation of lipopolysaccharides (LPS, endotoxin) as the principal structure of Gram-negative bacteria activating the human immune system, its Gram-positive counterpart is still under debate. Pyrogen tests based on the human monocyte activation have been validated for LPS detection as an alternative to the rabbit test and, increasingly, the limulus amebocyte lysate test. For full replacement, international validations with non-endotoxin pyrogens are in preparation. Following evidence-based medicine approaches, a systematic review of existing evidence as to the structural nature of the Gram-positive pyrogen was undertaken. For the three major constituents suggested, i.e., peptidoglycan, lipoteichoic acids (LTA), and bacterial lipoproteins (LP), the questions to be answered and a search strategy for relevant literature was developed, starting in MedLine. The evaluation was based on the Koch-Dale criteria for a mediator of an effect. A total of 380 articles for peptidoglycan, 391 for LP, and 285 for LTA were retrieved of which 12, 8, and 24, respectively, fulfilled inclusion criteria. The compiled data suggest that for peptidoglycan two Koch-Dale criteria are fulfilled, four for LTA, and two for bacterial LP. In conclusion, based on the best currently available evidence, LTA is the only substance that fulfills all criteria. LTA has been isolated from a large number of bacteria, results in cytokine release patterns inducible also with synthetic LTA. Reduction in bacterial cytokine induction with an inhibitor for LTA was shown. However, this systematic review cannot exclude the possibility that other stimulatory compounds complement or substitute for LTA in being the counterpart to LPS in some Gram-positive bacteria.Entities:
Keywords: cytokines; evidence-based medicine; lipoprotein; lipoteichoic acid; meta-analysis; peptidoglycan
Year: 2012 PMID: 22529809 PMCID: PMC3328207 DOI: 10.3389/fphar.2012.00056
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Isolation of different Gram-positive lipoproteins.
| Name | Bacteria | Reference | Isolation method |
|---|---|---|---|
| Isolation and characterization of a C12-lipopeptide produced by | Liu et al. ( | Chromatographic | |
| Isolation and structural analysis of bamylocin A, novel lipopeptide from | Lee et al. ( | Methanol, silica gel column chromatography, HPLC | |
| Isolation, characterization, and investigation of surface and hemolytic activities of a lipopeptide biosurfactant produced by | Dehghan-Noude et al. ( | HCl extraction | |
| Lichenysins G, a novel family of lipopeptide biosurfactants from | Grangemard et al. ( | HPLC | |
| Isolation and partial characterization of the Triton X-100 solubilized protein antigen from | Kim et al. ( | Triton X-100 | |
| WS1279, a novel lipopeptide isolated from | Tanaka et al. ( | Ethyl Acetate |
Figure 1Decision tree 1 (Koch–Dale criterion 1).
List of publications for isolation of LTA after application of decision tree 1.
| Name | Bacteria | Reference | Isolation method |
|---|---|---|---|
| Serological studies on the teichoic acids of | Knox and Wicken ( | Phenol, gel chromatography, gel chromatography, gel chromatography | |
| Comparative studies on the isolation of membrane lipoteichoic acid from | Wicken et al. ( | Chloroform–methanol | |
| Pneumococcal Forssman antigen. A choline-containing lipoteichoic acid | Pneumococci | Briles and Tomasz ( | Chloroform–octanol |
| Lipoteichoic acid localization in mesosomal vesicles of | Huff et al. ( | Chloroform–methanol | |
| Characterization of group N streptococcus lipoteichoic acid | Wicken and Knox ( | Phenol, gel chromatography | |
| Lipoteichoic acid and lipoteichoic acid carrier in | Duckworth et al. ( | Phenol, gel chromatography | |
| Extraction and purification of lipoteichoic acids from gram-positive bacteria | Coley et al. ( | Phenol, gel chromatography | |
| Cellular localization of lipoteichoic acid in | Joseph and Shockman ( | Phenol, gel chromatography | |
| Trihexosyldiacylglycerol and acyltrihexosyldiacylglycerol as lipid anchors of the lipoteichoic acid of | Nakano and Fischer ( | Phenol, gel chromatography | |
| Purification of lipoteichoic acids by using phosphatidyl choline vesicles | Silvestri et al. ( | Gel filtration, HIC | |
| Alanine ester-containing native lipoteichoic acids do not act as lipoteichoic acid carrier. Isolation, structural and functional characterization | Fischer et al. ( | HIC | |
| Isolation of a | Shockley and Kleinman ( | Phenol, gel chromatography | |
| Immunization of rhesus monkeys with | Caldwell and Lehner ( | Phenol, gel chromatography | |
| Association of elevated levels of cellular lipoteichoic acids of group B streptococci with human neonatal disease | Group B streptococci (GBS), different strains | Nealon and Mattingly ( | Phenol, gel chromatography |
| Improved preparation of Lipoteichoic acids | Fischer et al. ( | Phenol, gel chromatography, HIC | |
| Lipoteichoic acid from | Hether and Jackson ( | Phenol, gel chromatography | |
| Structure of the lipoteichoic acids from | Op den Camp et al. ( | Phenol, gel chromatography | |
| Activation of the alternative complement pathway by pneumococcal lipoteichoic acid | Hummell et al. ( | Chloroform–methanol | |
| Chemical properties and immunobiological activities of streptococcal lipoteichoic acids | Hamada et al. ( | Phenol, gel chromatography | |
| Comparative studies of lipoteichoic acids from several | Iwasaki et al. ( | Phenol, gel chromatography | |
| Lipoteichoic acids in | Sherman and Savage ( | Phenol, gel chromatography | |
| Structural studies on lipoteichoic acids from four | Uchikawa et al. ( | Phenol, gel chromatography | |
| Structural studies of a teichoic acid from | Erbing et al. ( | Phenol, gel chromatography | |
| Lipoteichoic acid from | Meyer and Wouters ( | Phenol, gel chromatography | |
| Mediation of | Teti et al. ( | Phenol, gel chromatography | |
| “Lipoteichoic acid” of | Fischer ( | Phenol, gel chromatography | |
| Stimulation of human monocyte chemiluminescence by staphylococcal lipoteichoic acid | Ohshima et al. ( | Phenol, gel chromatography | |
| Structure and glycosylation of lipoteichoic acids in | Iwasaki et al. ( | Phenol, gel chromatography | |
| Distribution analyses of chain substituents of lipoteichoic acids by chemical degradation | Schurek and Fischer ( | Phenol, gel chromatography | |
| Occurrence and structure of lipoteichoic acids in the genus | Ruhland and Fiedler ( | Phenol, gel chromatography | |
| On the basic structure of poly(glycerophosphate) lipoteichoic acids | 24 Gram-positive bacteria of the genera | Fischer et al. ( | Phenol, HIC |
| Structure of macroamphiphiles from several | Iwasaki et al. ( | Phenol, gel chromatography | |
| Isolation and characterization of lipoteichoic acid, a cell envelope component involved in preventing phage adsorption, from | Sijtsma et al. ( | Chloroform–methanol | |
| Molecular analysis of lipoteichoic acid from | Maurer and Mattingly ( | Phenol, gel chromatography | |
| Separation of the poly(glycerophosphate) lipoteichoic acids of | Leopold and Fischer ( | Phenol, gel chromatography, HIC | |
| Small and medium-angle X-ray analysis of bacterial lipoteichoic acid phase structure | Labischinski et al. ( | Phenol, gel chromatography, HIC | |
| Hydrophobic interaction chromatography fractionates lipoteichoic acid according to the size of the hydrophilic chain: a comparative study with anion-exchange and affinity chromatography for suitability in species analysis | Leopold and Fischer ( | Phenol, gel chromatography, HIC | |
| Pollack et al. ( | Phenol, gel chromatography | ||
| Molecular analysis of lipid macroamphiphiles by hydrophobic interaction chromatography, exemplified with lipoteichoic acids | Fischer ( | Phenol, gel chromatography, HIC | |
| The structure of pneumococcal lipoteichoic acid. Improved preparation, chemical, and mass spectrometric studies | Behr et al. ( | Chloroform–methanol | |
| Isomalto-oligosaccharide-containing lipoteichoic acid of | Kochanowski et al. ( | Phenol, gel chromatography, HIC | |
| Chemiluminescence of human polymorphonuclear leukocytes after stimulation with whole cells and cell wall components of | Martinez-Martinez et al. ( | Phenol, gel chromatography | |
| Competitive binding of calcium and magnesium to streptococcal lipoteichoic acid | Rose and Hogg ( | Phenol, gel chromatography, HIC | |
| Lipoteichoic acid inhibits remineralization of artificial subsurface lesions and surface-softened enamel | Damen et al. ( | Phenol, gel chromatography | |
| Cytokine-inducing glycolipids in the lipoteichoic acid fraction from | Suda et al. ( | Chloroform–methanol | |
| A lipoteichoic acid fraction of | Arakaki et al. ( | Phenol, HIC | |
| Structure-function relationship of cytokine induction by lipoteichoic acid from | Morath et al. ( | Butanol-HIC | |
| Production of IL-12 and IL-18 in human dendritic cells upon infection by | Kolb-Maurer et al. ( | Phenol, gel chromatography | |
| Characterization of lipoteichoic acids as | Raisanen et al. ( | Phenol, gel chromatography | |
| Monoacyl lipoteichoic acid from pneumococci stimulates human cells but not mouse cell | Kim et al. ( | Phenol, gel chromatography, ion-exchange chromatography | |
| Highly purified lipoteichoic acid from gram-positive bacteria induces | Boveri et al. ( | Butanol-HIC | |
| Comparison of lipoteichoic acid from different serotypes of | Draing et al. ( | Butanol-HIC | |
| Opsonic antibodies to | Theilacker et al. ( | Butanol-HIC | |
| Butanol-extracted lipoteichoic acid induces | Finney et al. ( | Butanol-HIC | |
| Lipoteichoic acid isolated from | Kim et al. ( | Butanol-HIC | |
| Macroamphiphilic components of thermophilic actinomycetes: identification of lipoteichoic acid in | Rahman et al. ( | Butanol-HIC | |
| Differential immunostimulatory effects of Gram-positive bacteria due to their lipoteichoic acids | Ryu et al. ( | Butanol-HIC | |
| Phenotypic variation in | Rahman et al. ( | Butanol-HIC |
Figure 2Decision tree 2 (Koch–Dale criterion 2).
Results for Koch–Dale criterion 2 for bacterial lipoproteins and LTA.
| Reference | Bacteria | Mutation | Cytokines | Outcome |
|---|---|---|---|---|
| | ||||
| Stoll et al. ( | Diacylglycerol transferase (lgt) deletion | IL-6, IL-8, MCP-1, TNF, IL-10 | S.a.Δlgt attenuated in growth in nutrient limited medium, induction of cytokines is reduced | |
| Wilkinson et al. ( | Mutation in Delta 19 gene responsible for the production of the 19-kDa lipoprotein | IL-1β, TNF, IL-12 | M.t. Δ19 leads to reduced IL-1β induction, but TNF and IL-12 release is unaffected | |
| Rusch et al. ( | Mutation in Delta 19 gene responsible for the production of the 19-kDa lipoprotein | IL-1β, TNF | M.t. Δ19 leads to reduced IL-1β induction, but TNF release is unaffected | |
| | ||||
| Perea Velez et al. ( | Deletion of dlt operon responsible for LTA alanylation | IL-10, TNF | IL-10 release significantly reduced for dlt mutant, TNF unaffected compared to wt | |
| Grangette et al. ( | Deletion of dlt operon responsible for LTA alanylation | TNF, IL-12, IFNγ, IL-10 | TNF, IL-12, and INFγ significantly reduced for dlt mutant, IL-10 increased | |
Figure 3Decision tree 3 (pre-selection of the literature for Koch–Dale criteria 3 and 4).
Publications after fulfillment of decision tree for K/D criterion 3 for LTA.
| Reference | Substance | Source of substance | Cytokines | Cells | Endotoxin exclusion |
|---|---|---|---|---|---|
| Deininger et al. ( | LTA | Synthetic | TNF, IL-8 | Whole blood | LAL |
| Hasiwa et al. ( | PGN, LTA | Commercial, isolated | IL-1β | Whole blood | LAL |
| Deininger et al. ( | LTA | Isolated | IL-8, IL-1β, IL-6, TNF, G-CSF, IL-10 | Whole blood | LAL |
| Kim et al. ( | LTA | Isolated, commercial | IL-10, IL-23 | THP-1 | Poly B |
| Uehara et al. ( | LTA, PGN | Commercial | IL-8 | IFN primed HSC2 | Poly B |
| Wang et al. ( | LTA, PGN | Isolated | TNF, IL-1β, IL-6 | Whole blood | Poly B |
| Bucki et al. ( | LTA | Commercial | IL-8 | Neutrophils | LAL |
| Meron-Sudai et al. ( | LTA, PAM3 | Isolated | IL-1β | Whole blood, monocytes | LAL |
| Kim et al. ( | LTA | Isolated | TNF | THP-1 | LAL |
| Draing et al. ( | LTA | Isolated | TNF | Whole blood, PBMC | LAL |
| Draing et al. ( | LTA | Isolated | TNF-, IL-8, IL-10, G-CSF, IL-1β | PBMC, whole blood | LAL |
| Mueller et al. ( | LTA | Isolated | TNF, IL-6 | PBMC, Monocytes | Not TLR4 dependent |
| Levels et al. ( | LTA | Commercial | TNF | Whole blood | LAL (<19 ng/mg LTA |
| Deininger et al. ( | LTA | Synthetic | IL-1β, TNF, IL-6, IL-8, IL-10 | Whole blood | LAL |
| Morath et al. ( | LTA | Isolated, synthetic | TNF, IL-1β, IL-6, IL-10 | Whole blood, PBMC | LAL |
| Morath et al. ( | LTA | Isolated | TNF | Whole blood | LAL |
| Kim et al. ( | MDP, LTA | Commercial, isolated | TNF-, IL-12 p40, and IL-10 | DC | – |
| Henneke et al. ( | LTA | Isolated, commercial | IL-8 | PBMC, HEK293 | – |
| Grangette et al. ( | LTA | Isolated | IL-1β, TNF, IL-8, IL-6 | PBMC | – |
| Schroder et al. ( | LTA | Isolated | TNF | PBMC | – |
| Jacinto et al. ( | LTA | Isolated | TNF, IL-1β | THP-1 | Not TLR4 dependent |
| Plitnick et al. ( | LTA | Isolated | IL-2 | PBMC | – |
| Talreja et al. ( | PGN, LTA | Commercial | IL-6 | HUVEC | Poly B |
| Morath et al. ( | LTA | Synthetic | TNF | Whole blood | – |
| Stadelmaier et al. ( | LTA | Synthetic | TNF, IL-8 | Whole blood | – |
| Into et al. ( | PGN, LTA | Commercial | IL-10 | THP-1 | – |
Publications after fulfillment of decision tree for K/D criterion 3 for PGN.
| Reference | Substance | Source of substance | Cytokines | Cells | Endotoxin |
|---|---|---|---|---|---|
| Wolfert et al. ( | PGN, muramyl dipeptide (MDP) | Isolated, commercial | TNF | MonoMac-6 | Poly B |
| McCurdy et al. ( | LP, PGN | Isolated, commercial | IL-1β, IL-6, RANTES, GM–CSF | Cord blood-derived mast cells (CBMC) | LAL |
| Wang et al. ( | LTA, PGN | Isolated | TNF, IL-1β, IL-6 | Whole blood | Poly B |
| Langer et al. ( | PGN | Isolated | TNF | Whole blood | Poly B |
| Natsuka et al. ( | PGN | Isolated | IL-8 | THP-1 | LAL |
| Uehara et al. ( | MDP, PGN | Commercial | IL-8 | THP-1 | – |
| Into et al. ( | PGN, LTA | Commercial | IL-10 | THP-1 | – |
| Eriksson et al. ( | PGN | Commercial | IL-12, IL-15 | THP-1 | – |
| Uehara et al. ( | PGN | Commercial, isolated | IL-8, MCP-1, IL-6, and TNF | THP-1 | – |
Publications after fulfillment of decision tree for K/D criterion 3 for synthetic LP and recombinant or isolated LP.
| Reference | Substance | Source of substance | Cytokines | Cells | Endotoxin |
|---|---|---|---|---|---|
| | |||||
| Wang et al. ( | LP | Commercial | TNF, IL-6 | THP-1 | LAL |
| Schromm et al. ( | LP | Isolated | TNF, IL-8 | Monocytes, HEK293 | Poly B |
| McCurdy et al. ( | LP, PGN | Isolated, commercial | IL-1, IL-6, RANTES, GM–CSF | Cord blood-derived mast cells (CBMC) | LAL |
| Schroder et al. ( | LP | Commercial | TNF | PBMC | – |
| Sieling et al. ( | LP | Commercial | IL-12 p40, GM–CSF, IL-4 | PBMC | – |
| | |||||
| Wu et al. ( | Commercial, isolated | TNF, IL-1β, IL-6 | THP-1 | Poly B | |
| DiRita et al. ( | L-OSPA | Commercial, isolated | IL-6, IL-10, IL-12 (p40), TNF, IL-1β | THP-1 | LAL |
| Giambartolomei et al. ( | L-OSPA | Commercial, isolated | IL-6, IL-10, and IL-12 | THP-1 | LAL |
Fulfillment of the four K/D criteria for LTA, PGN, and LP (criteria: 1–5 publications: +; 6–10 publications: ++; >10 publications: +++).
| LTA | PGN | LP | |
|---|---|---|---|
| K/D 1 | +++ | Ubiquitous | − |
| K/D 2 | + | Not possible | + |
| K/D 3 | +++ | ++ | ++ |
| K/D 4 | + | − | − |
Fulfillment of Bradford Hill criteria for LTA, PGN, and LP (personal weighing of evidence by the authors as explained in the text).
| LTA | PGN | LP | |
|---|---|---|---|
| Strength | +++ | − | − |
| Consistency | +++ | +++ | − |
| Specificity | ++ | − | + |
| Temporality | +++ | +++ | +++ |
| Biological Gradient | +++ | +++ | +++ |
| Plausibility | +++ | + | ++ |
| Coherence | +++ | − | − |